Evidence map›Paper›PMID 25949907›Full record

ArticleOncoimmunology2015

NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.

Takumi Kobayashi, Brianna L Doff, Rory C Rearden, Graham R Leggatt, Stephen R Mattarollo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 38 citations in OpenAlex.

  1. CD8Cell reports. Medicine · 2026
    Review
  2. Article
  3. Review
  4. The role of KLRG1: a novel biomarker and new therapeutic target.Cell communication and signaling : CCS · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. CD137Cancers · 2021
    Review
  9. Review
  10. Article
  11. Review
  12. Mouse Models ofFrontiers in immunology · 2020
    Review
  13. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.International journal of molecular sciences · 2019
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Takumi KobayashiThe University of Queensland Diamantina Institute; The University of Queensland; Translational Research Institute, Brisbane ; Queensland, Australia.
Brianna L DoffThe University of Queensland Diamantina Institute; The University of Queensland; Translational Research Institute, Brisbane ; Queensland, Australia.
Rory C ReardenThe University of Queensland Diamantina Institute; The University of Queensland; Translational Research Institute, Brisbane ; Queensland, Australia.
Graham R LeggattThe University of Queensland Diamantina Institute; The University of Queensland; Translational Research Institute, Brisbane ; Queensland, Australia.
Stephen R MattarolloThe University of Queensland Diamantina Institute; The University of Queensland; Translational Research Institute, Brisbane ; Queensland, Australia.
Diamant (Germany) · DEUniversity of Queensland · AURetina Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Harnessing the immune adjuvant properties of natural killer T (NKT) cells is an effective strategy to generate anticancer immunity. The objective of this study was to increase the potency and durability of vaccine-induced immunity against B cell lymphoma by combining α-galactosylceramide (α-GalCer)-loaded tumor cell vaccination with an agonistic antibody targeting the immune checkpoint molecule 4-1BB (CD137). We observed potent synergy when combining vaccination and anti-4-1BB antibody treatment resulting in significantly enhanced survival of mice harboring Eμ-myc tumors, including complete eradication of lymphoma in over 50% of mice. Tumor-free survival required interferon γ (IFNγ)-dependent expansion of CD8

Indexed as

4–1BBB cell lymphomacancer vaccinecIg: isotype control immunoglobulinCRs, complete responsesDPEC, double positive effector cellsEEC, early effector cellshematological malignanciesimmune checkpoint moleculeimmunotherapyKO, knock-outmAb, monoclonal antibodymonoclonal antibodyMPEC, memory precursor effector cellsNKT cellsSLEC, short-lived effector cellsWT, wild-type.α-galactosylceramideα-GalCer, α-galactosylceramide

Identifiers

PMID25949907
PMCPMC4404843
OpenAlexW1988685761

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.